Journal of Gastroenterology

, Volume 41, Issue 7, pp 613–625

Autoimmune pancreatitis: proposal of IgG4-related sclerosing disease

  • Terumi Kamisawa
  • Atsutake Okamoto
Open Access
Review

Abstract

Autoimmune pancreatitis (AIP) is a peculiar type of pancreatitis of presumed autoimmune etiology. Many new clinical aspects of AIP have been clarified during the past 10 years, and AIP has become a distinct entity recognized worldwide. However, its precise pathogenesis or pathophysiology remains unclear. As AIP dramatically responds to steroid therapy, accurate diagnosis of AIP is necessary to avoid unnecessary surgery. Characteristic dense lymphoplasmacytic infiltration and fibrosis in the pancreas may prove to be the gold standard for diagnosis of AIP. However, since it is difficult to obtain sufficient pancreatic tissue, AIP should be diagnosed currently based on the characteristic radiological findings (irregular narrowing of the main pancreatic duct and enlargement of the pancreas) in combination with serological findings (elevation of serum γ-globulin, IgG, or IgG4, along with the presence of autoantibodies), clinical findings (elderly male preponderance, fluctuating obstructive jaundice without pain, occasional extrapancreatic lesions, and favorable response to steroid therapy), and histopathological findings (dense infiltration of IgG4-positive plasma cells and T lymphocytes with fibrosis and obliterative phlebitis in various organs). It is apparent that elevation of serum IgG4 levels and infiltration of abundant IgG4-positive plasma cells into various organs are rather specific to AIP patients. We propose a new clinicopathological entity, “IgG4-related sclerosing disease” and suggest that AIP is a pancreatic lesion reflecting this systemic disease.

Key words

autoimmune pancreatitis IgG4 chronic pancreatitis sclerosing cholangitis retroperitoneal fibrosis 

Introduction

In 1961, Sarles et al.1 first reported pancreatitis associated with hypergammaglobulinemia and suggested autoimmunity as a pathogenetic mechanism. Since then, the possible role of autoimmunity in causing chronic pancreatitis has drawn the attention of several investigators. In 1992, Toki et al.2 reported four cases of an unusual type of chronic pancreatitis showing diffuse irregular narrowing of the entire main pancreatic duct. In 1995, Yoshida et al.3 summarized the clinical features of these patients and proposed the concept of autoimmune pancreatitis (AIP). Since then, many cases of AIP have been reported in Western countries as well as in Japan. Many new clinical aspects of AIP have been clarified during the past 10 years, and AIP has become a distinct entity recognized worldwide.4, 5, 6

After histologically and immunohistochemically examining various organs and extrapancreatic lesions of AIP patients, we proposed the existence of a novel clinicopathological entity, “IgG4-related sclerosing disease”, and suggested that AIP is not simply pancreatitis but a pancreatic lesion reflecting this systemic disease.7,8 Recently, IgG4-related sclerosing diseases of organs other than the pancreas have been reported.9, 10, 11, 12, 13, 14 Based on our experience with 32 cases of AIP, this review focuses on the clinical, laboratory, imaging, and histopathological features of IgG4-related sclerosing disease as well as AIP. MEDLINE was searched from 1992 to May 2006 for relevant English-language articles, using a combination of the terms autoimmune pancreatitis, sclerosing pancreatitis, sclerosing cholangitis, sclerosing sialadenitis, retroperitoneal fibrosis, and IgG4. Additional sources were identified by scanning the bibliographies of original and review articles.

Autoimmune pancreatitis

Concept of AIP

AIP is a unique form of pancreatitis in which autoimmune mechanisms are suspected to be involved in the pathogenesis. AIP has many clinical, radiological, serological, and histopathological characteristics as follows: (1) elderly male preponderance; (2) frequent initial symptom of obstructive jaundice without pain; (3) occasional association with impaired pancreatic endocrine or exocrine function and various extrapancreatic lesions; (4) a favorable response to steroid therapy; (5) radiological findings of irregular narrowing of the main pancreatic duct and enlargement of the pancreas; (6) serological findings of elevation of serum γ-globulin, IgG, or IgG4 levels, along with the presence of some autoantibodies; and (7) histopathological findings of dense lymphoplasmacytic infiltration with fibrosis and obliterative phlebitis in the pancreas.15, 16, 17 Typical AIP shows diffuse changes of the pancreas, but several cases have shown segmental changes. Localized AIP may extend progressively to the whole pancreas.18,19 The current concept of AIP, including associated extrapancreatic lesions, suggests that AIP may be a systemic disease.7,8,20,21

AIP has been described by various names reflecting different aspects of the entity and each emphasizing the clinical, radiological, or histological findings: for example, chronic inflammatory sclerosis of the pancreas,1 duct-narrowing chronic pancreatitis (DNCP),2 lymphoplasmacytic sclerosing pancreatitis,22 nonalcoholic duct destructive chronic pancreatitis,23 and idiopathic tumefactive chronic pancreatitis.24

Prevalence

AIP is a rare disorder, but its exact incidence is unknown. In a nationwide survey conducted in Japan, 900 patients with AIP were identified,25 and the total number of patients treated for chronic pancreatitis in a year was estimated as 44 700.26 The prevalence rate of AIP among patients with chronic pancreatitis was 1.95% in this survey. We encountered 32 patients (8.4%) with AIP out of 380 patients with chronic pancreatitis clinically diagnosed in our institute. Other reported prevalence rates of AIP among chronic pancreatitis cases are 4.6% (21/451) in Japan,27 5.4% (17/315) in Korea,16 and 6.0% (23/383) in Italy.27 In North America, about 2.5% of pancreatoduodenectomies are performed for AIP because of a mistaken diagnosis of pancreatic cancer,28 and AIP cases represent between 21%29 and 23%28 of pancreatoduodenectomies performed for benign conditions. Reported AIP cases are increasing with the growing awareness of this entity around the world.

Pathogenesis

Serum IgG4 is a subtype of IgG, and its levels are frequently elevated and particularly high in AIP.30,31 Dense infiltration of IgG4-positive plasma cells is seen in various organs of AIP patients.7,8,32, 33, 34 These results suggest that IgG4 plays a major role in the pathogenesis of AIP, although the trigger for the IgG4 elevation or its pathogenetic role in AIP has not been clearly disclosed. Antilactoferrin and anti-carbonic anhydrase II (CA-II) antibodies are frequently detected in AIP patients.35 Therefore, lactoferrin and CA-II have been proposed as the target antigens, but this has not yet been fully confirmed. Although the actual effector cells of AIP have not been clearly delineated, the number of activated CD4- and CD8-positive T cells bearing HLADR is increased among the peripheral blood lymphocytes and in the pancreas of AIP patients.35 It has also been reported that this disease is closely associated with the HLA DRB1*0405-DQB1*0401 haplotype, suggesting that the specific peptide presented by these HLA molecules triggers the pathological process of the autoimmunity.36

Although the many above-mentioned findings support an immunologic mechanism of AIP, target antigens for AIP have not been detected. Its preponderant occurrence in elderly men and markedly dramatic response to oral steroid therapy suggest that the pathogenesis of AIP might not be by an autoimmune mechanism but by some other mechanism such as an allergic reaction.

Clinical manifestations

AIP occurs predominantly in elderly men.37 In our series, the mean age of the patients was 68.3 years (range, 29–83 years) and the male-to-female ratio was 4 : 1. In a study in Korea, the mean age was 59.1 years (45–75 years), and the male-to-female ratio was 15:2.16 Patients rarely show typical features of pancreatitis, and the major presenting complaint is painless obstructive jaundice due to associated sclerosing cholangitis (65%16 or 86%38 of cases). The jaundice sometimes fluctuates. Diabetes mellitus, usually type 2, is often (41%39 or 76%16 of cases) observed. In many cases, the diagnoses of diabetes mellitus and AIP are made simultaneously; some patients show exacerbation of preexisting diabetes mellitus with the onset of AIP.40 Tanaka et al.41,42 reported that diabetes mellitus with AIP was caused by T-cell-mediated mechanisms primarily involving islet β-cells as well as pancreatic duct cells. Pancreatic exocrine function is frequently impaired, but marked pancreatic insufficiency is uncommon.43 Some patients have other symptoms related to associated diseases, including salivary gland swelling due to sclerosing sialadenitis, hydronephrosis due to retroperitoneal fibrosis, and lymphadenopathy.44

Laboratory findings

Few patients show marked elevation of serum pancreatic enzymes. The patients with biliary lesions show elevation of serum bilirubin and hepatobiliary enzymes. Some patients show peripheral eosinophilia or elevation of serum IgE levels. Hypergammaglobulinemia (>2.0 g/dl) and elevated serum IgG levels (>1800 mg/dl) are detected in 59%–76%45, 46, 47 and 53%16–71%45 of AIP patients, respectively. A diagnostic autoantibody for AIP has not been detected. Autoantibodies including antinuclear antibody and rheumatoid factor are present in 43%–75%39,46,47 and 13%–30%39,46,47 of patients, respectively. Serological findings may change spontaneously during the course of AIP.48 In 2001, Hamano et al.30 reported that serum IgG4 levels are significantly and specifically high in AIP patients and are closely associated with disease activity. According to their report, the use of a cutoff value of 135 mg/dl for the serum IgG4 level resulted in a high rate of accuracy (97%), sensitivity (95%), and specificity (97%) for differentiating AIP from pancreatic cancer. Some AIP patients show elevated serum IgG4 levels in spite of normal IgG levels. However, the sensitivity of elevated serum IgG4 levels is 63%–68% in other reports.15,16,49 Elevation of serum IgG4 levels has been reported in a patient with pancreatic cancer.50

Radiological findings

Typical cases of AIP show diffuse enlargement of the pancreas, the so-called sausage-like appearance, on computed tomography (CT), ultrasonography (US), and magnetic resonance image (MRI). On dynamic CT and MRI, there is delayed enhancement of the swollen pancreatic parenchyma (Fig. 1a).47,51, 52, 53 The affected pancreatic lesion shows decreased intensity on the T1-weighted image and increased intensity on the T2-weighted image compared with the signal intensity in the liver.51,53,54 Since inflammatory and fibrous changes involve the peripancreatic adipose tissue, a capsule-like rim surrounding the pancreas, which appears as a low-density area on CT and as a hypointense area on a T2-weighted MRI (Fig. 1b), is detected in some cases.47,51, 52, 53, 54 US shows an enlarged hypoechoic pancreas with hyperechoic spots (Fig. 1c).47,51,53 Pancreatic calcification or pseudocyst is uncommon. Some cases show a focal enlargement of the pancreas, similar to that seen with pancreatic cancer.47,55, 56, 57 On endoscopic retrograde cholangiopancreatography, an irregular, narrow main pancreatic duct is seen diffusely throughout the pancreas in typical cases. The degree of narrowing of the main pancreatic duct varies in the same patient (Fig. 1d). In some cases, there is segmental narrowing of the main pancreatic duct, but upstream dilatation of the distal pancreatic duct is less often noted than in pancreatic cancer (Fig. 1e).47,57 In a majority of AIP patients, both the ventral and dorsal pancreatic ducts are involved, while some patients show the involvement of only the dorsal pancreatic duct. Patients without involvement of the ventral pancreas tend rarely to present with obstructive jaundice.58,59 Stenosis of the extrahepatic or intrahepatic bile duct is frequently observed (Fig. 1e). Marked wall thickening of the extrahepatic bile duct or gallbladder is sometimes detected on US or endoscopic ultrasonography (EUS).53,60,61 Magnetic resonance cholangiopancreatography does not adequately show the narrow portion of the main pancreatic duct,54 but it can adequately demonstrate stenosis of the bile duct with dilatation of the upper biliary tract.53 Cervical, hilar, and abdominal lymphadenopathy is sometimes detected on CT.47,49 On angiography, encasement of the peripancreatic arteries and stenosis of the portal vein are sometimes observed.47,62 F-18 fluorodeoxyglucose (FDG) positron emission tomography occasionally demonstrates intense FDG uptake in the pancreas of AIP patients.63, 64, 65
Fig. 1a–f

Radiological findings of patients with autoimmune pancreatitis. a Diffuse enlargement of the pancreas showing delayed enhancement on computed tomography scan. b A hypointense capsule-like rim surrounding the swollen pancreas on a T2-weighted magnetic resonance image. c Diffuse hypoechoic swollen pancreas with hyperechoic spots on US. d Diffuse irregular narrowing of the main pancreatic duct on endoscopic retrograde pancreatography. Degree of narrowing varies. e Stenosis of the lower bile duct and segmental narrowing of the main pancreatic duct of the pancreatic head on endoscopic retrograde cholangiopancreatography. Upstream dilatation of the distal pancreatic duct is less noted than with pancreatic cancer. f After steroid therapy, both stenosis of the bile duct and narrowing of the main pancreatic duct (e) improved

Histopathological and immunohistochemical findings

In gross appearance, the pancreas in AIP shows firm and mass-like enlargement with a thick capsule. The hallmark of the histological findings in the pancreas of AIP patients is dense inflammatory cell infiltration and fibrosis in a periductal and interlobular distribution (Fig. 2a). The inflammatory infiltrate consists mainly of lymphocytes and plasma cells with occasional formation of lymphoid follicles. Perineural infiltration is sometimes detected. Fibrosis is usually diffuse and dense, but loose with stromal edema in some cases. The acinar cells are then more or less replaced by inflammatory cells and fibrosis, and the lobular architecture of the pancreas is almost lost. The pancreatic duct is narrowed by periductal fibrosis and lymphoplasmacytic infiltration (Fig. 2b). The infiltrate is primarily subepithelial, and the ductal epithelium is usually preserved except for sparse infiltration by lymphocytes. This is appropriately labeled as lymphoplasmacytic sclerosing pancreatitis. Another highly characteristic histological finding is obliterative phlebitis of the variably sized pancreatic veins and involvement of the portal vein with lymphoplasmacytic infiltrate and proliferation of fibroblasts in and around the wall of the vein (Fig. 2c). Such an inflammatory process widely and intensely involves the contiguous soft tissue and peripancreatic retroperitoneal tissue.22,32,66, 67, 68, 69 Saito et al.70 reported that histological recovery of the pancreas, including amelioration of the fibrosis and infiltration of inflammatory cells and a substantial increase in the number of acinar cells, was detected in a patient with AIP after steroid therapy. The wall of the bile duct and gallbladder thickens, histologically showing the same inflammatory process as that of the pancreas. Regional lymph nodes are swollen up to 2.0 cm in diameter, and show histologically marked follicular hyperplasia and dense plasmacytic infiltration in the paracortical and medullary regions.22,32
Fig. 2a–c

Histological findings of the pancreas of patients with autoimmune pancreatitis. a Prominent periductal and interlobular fibrosis with a dense lymphoplasmacytic infiltration and acinar destruction (hematoxylin-eosin stain) b Pancreatic duct narrowed by periductal nonocclusive fibrosis and lymphoplasmacyticinfiltration (elastica-van Gieson stain) c Obliterative phlebitis of the pancreatic veins with prominent lymphoplasmacytic infiltrate and fibrosis (elastica-van Gieson stain)

These characteristic histological findings of AIP are detected during its active phase, and may be a gold standard for diagnosing AIP.71 However, diagnosing AIP on the basis of a biopsy or an EUS-guided fine-needle aspiration biopsy is sometimes difficult, because of the small sample size.

Immunohistochemically, infiltrating inflammatory cells in the pancreas consist of CD4- or CD8-positive T lymphocytes and IgG4-positive plasma cells (Fig. 3a). Dense infiltration [>30/high-power field (hpf)] of IgG4-positive plasma cells in the pancreas is not observed in chronic alcoholic pancreatitis or pancreatic cancer. Infiltration of abundant IgG4-positive plasma cells is also detected in various organs such as the peripancreatic retroperitoneal tissue, major duodenal papilla, biliary tract, intrahepatic periportal area (Fig. 3b), salivary glands (Fig. 3c), gastric mucosa, colonic mucosa, lymph nodes (Fig. 3d), or bone marrow of AIP patients.7,8,32, 33, 34
Fig. 3a–e

IgG4-immunostaining of various organs of patients with autoimmune pancreatitis. Dense infiltration of IgG4-positive plasma cells was detected in the pancreas (a), periportal area of the liver (b), salivary gland (c), lymph node (d), and associated retroperitoneal fibrous mass (e)

Diagnostic criteria and differential diagnosis

As it is usually difficult to take specimens from the pancreas, currently, AIP should be diagnosed on the basis of combination with clinical, laboratory, and imaging studies. The Japan Pancreas Society has proposed “Diagnostic Criteria for Autoimmune Pancreatitis, 2002,” containing three items: (1) radiological imaging showing diffuse enlargement of the pancreas and diffuse irregular narrowing of the main pancreatic duct (more than one-third the length of the entire pancreas); (2) laboratory data demonstrating abnormally elevated levels of serum γ-globulin or IgG, or the presence of autoantibodies; and (3) histological examination of the pancreas showing lymphoplasmacytic infiltration and fibrosis. For the diagnosis of AIP, either all of the criteria should be present or criterion 1 together with either criterion 2 or criterion 3. The presence of the imaging criterion is essential for diagnosing AIP.27,72 These criteria are based on the minimum consensus features of AIP to avoid a misdiagnosis pancreatic cancer as far as possible. However, the accumulation of many AIP cases has revealed several diagnostic limitations to these criteria, and revised criteria has been proposed in 2006.73 According to these new criteria, cases showing localized ductal narrowing over less than one-third the length of the pancreas can be diagnosed, and serological findings showing elevation of the serum IgG4 level is included as one diagnostic factor. Recently, new diagnostic criteria have been proposed in Korea74 and the United States75 that include two more factors: response to steroid therapy and other-organ involvement.

The most important disease that should be differentiated from AIP is pancreatic cancer. Clinically, patients with pancreatic cancer and AIP share many features, such as being elderly, having painless jaundice, developing new-onset diabetes mellitus, and having elevated tumor markers.47 Radiologically, focal swelling of the pancreas, the “double-duct sign,” representing strictures in both the biliary and pancreatic ducts, as well as angiographic abnormalities can sometimes be seen in both pancreatic cancer and AIP. As AIP responds dramatically to steroid therapy, accurate diagnosis of AIP can avoid unnecessary laparotomy or pancreatic resection. Imaging findings, such as a mass showing delayed enhancement and a capsule-like rim on dynamic CT or MRI, and segmental narrowing of the main pancreatic duct associated with a less-dilated upstream pancreatic duct, are all useful in differentiating pancreatic cancer from AIP. Measurement of serum IgG4 levels is a useful tool for differentiating between the two diseases. We preliminarily reported that IgG4-immunostaining of biopsy specimens taken from the major duodenal papilla of AIP patients may support the diagnosis of AIP.76 Although improvement in clinical findings with steroid therapy may be useful in the differential diagnosis of AIP from pancreatic cancer, empiric administration of steroids should be avoided in order not to misdiagnose pancreatic cancer as AIP.

It is of uppermost importance to consider the possible presence of AIP in elderly patients presenting with obstructive jaundice and a pancreatic mass.

Treatment and prognosis

Some AIP patients improve spontaneously.77,78 Steroid therapy is clinically, morphologically, and serologically effective in AIP patients (Fig. 1e,1f). In cases with obstructive jaundice, endoscopic or percutaneous transhepatic biliary drainage must be done, and in cases of diabetes mellitus, glucose levels must be controlled before steroid therapy is started. The preferred initial dose of prednisolone is 30–40 mg/day, and it is tapered by 5 mg every 1–2 weeks. Serological and imaging tests are performed periodically after commencement of steroid therapy. Usually, pancreatic size is normalized within a few weeks, and biliary drainage becomes unnecessary within 1–2 months. Patients in whom complete radiological improvement is documented can stop their medication, but most other patients require continued maintenance therapy with prednisolone 5 mg/day.78 In half of steroid-treated patients, impaired exocrine or endocrine function improves.40,43 Some AIP patients relapse during maintenance therapy or after stopping steroid medication and should be retreated with high-dose steroid therapy. The indications for steroid therapy in AIP include obstructive jaundice due to stenosis of the bile duct or the presence of other associated systemic diseases, such as retroperitoneal fibrosis.79 Steroid therapy is also effective for sclerosing cholangitis that relapses after surgery.80,81

The long-term prognosis of AIP is not well known. In our 1- to 22-year follow-up study of AIP patients, the prognosis was almost always good, except in two patients who progressed to pancreatic insufficiency after resection.82 It has been reported that recurrent attacks of AIP result in pancreatic stone formation in some cases.38

Clinical subtype

Some young patients suffer from AIP. These young AIP patients are more likely to have abdominal pain and serum amylase elevation than middle-aged or elderly patients.83 According to American66 and Italian67 reports, AIP patients with neutrophilic infiltration in the epithelium of the pancreatic duct are younger, more commonly have inflammatory bowel disease, and have a weaker association with sialadenitis than patients without neutrophilic infiltration. AIP might be a heterogeneous disease with different clinical aspects, and these patients with young onset might be another subtype from the usual AIP as defined in Japan.84 Further international study of a larger series of clinically relevant subtypes of AIP is necessary.

Extrapancreatic lesions of AIP

AIP patients frequently have various extrapancreatic lesions. Since these extrapancreatic lesions show similar histopathological findings to those in the pancreas, they are possibly induced by the same IgG4-related fibroinflammatory mechanisms as AIP.

Multifocal fibrosclerosis is an uncommon fibroproliferative systemic disorder with multiple manifestations, including sclerosing cholangitis, fibrosis of the salivary glands, retroperitoneal fibrosis, Riedel’s thyroiditis, and fibrotic pseudotumor of the orbit. As histopathological findings of these disorders are similar, fibrotic changes with lymphoplasmacytic infiltration and occasional phlebitis, it has been suggested that they are all interrelated and probably represent different manifestations of a common disorder of fibroblastic proliferation.85 Several cases of pancreatic pseudotumor or chronic pancreatitis associated with multifocal fibrosclerosis have been reported.86, 87, 88, 89 The development of specific inflammation in extensive organs as well as in the pancreas in AIP patients strongly suggests a close relationship between AIP and multifocal fibrosclerosis.32

Sclerosing cholangitis

Sclerosing cholangitis is a heterogeneous disease that may be associated with choledocholithiasis, biliary tumor, or infection. Sclerosing cholangitis of unknown origin is called primary sclerosing cholangitis (PSC). PSC is progressive, despite conservative therapy, and involves the intra- and extrahepatic bile ducts, resulting in liver cirrhosis. The effect of steroid therapy is questionable, and liver transplantation currently provides the greatest hope for a possible cure. It occurs in patients in their 30s and 40s and is frequently associated with inflammatory bowel disease.90,91 The pancreatogram is not abnormal in most cases.92

Sclerosing cholangitis is frequently associated with AIP. In many cases, the stenosis is located in the lower part of the common bile duct (Fig. 1e), but EUS or intraductal ultrasonography shows wall thickening of the common bile duct even in the segment in which abnormalities are not clearly observed with cholangiography.60,61 When stenosis is found in the intrahepatic or the hilar hepatic bile duct, the cholangiographic appearance is very similar to that of PSC.92,93 Sclerosing cholangitis associated with AIP responds dramatically well to steroid therapy.79,92,93 The histological findings of sclerosing cholangitis associated with AIP include transmural fibrosis and dense lymphoplasmacytic infiltration of the bile duct wall along with lymphoplasmacytic infiltration and fibrosis in the periportal area of the liver. Compared with PSC, lymphoplasmacytic infiltration is more dense, the degree of fibrosis is less severe, and onion skin appearance is rarely observed. Dense infiltration of IgG4-positive plasma cells has been detected in the bile duct wall and the periportal area of patients with AIP, but it has not been detected in those of patients with PSC.7,8 Furthermore, elevation of serum IgG4 levels was not detected in our three patients with PSC. Given the age at onset, associated diseases, pancreatographic findings, response to steroid therapy, prognosis, and IgG4-related serological and immunohistochemical data, sclerosing cholangitis associated with AIP should be differentiated from PSC.92,93 In particular, discrimination between the two diseases is necessary before making therapeutic decisions.

Recently, three cases (in a 50-year-old woman, a 56-year-old man, and a 77-year-old man) of sclerosing cholangitis with elevated serum IgG4 levels and dense infiltration of IgG4-positive plasma cells in the bile duct wall but with no apparent pancreatic lesions compatible with AIP were reported.9 It is likely that these patients had an IgG4-related systemic disease with no clinical manifestations other than sclerosing cholangitis.

Sclerosing sialadenitis (Kuttner’s tumor and Mikulicz’s disease)

Sclerosing sialadenitis has been referred to as Kuttner’s tumor, on account of its presentation as a firm swelling of the salivary gland that is difficult to differentiate from a neoplasm.94 Mikulicz’s disease is a unique condition that involves enlargement of the lachrymal and salivary glands associated with prominent mononuclear infiltration.95 The pathogenesis of Kuttner’s tumor and Mikulicz’s disease is unknown.

Some cases of AIP associated with Sjögren’s syndrome have been reported.87,96 In our series, swelling of the salivary glands was detected in 7 of 30 (23%) patients with AIP, and it was associated with cervical or mediastinal lymphadenopathy. In these patients, the salivary glands showed dense infiltration of IgG4-positive plasma cells and fibrosis. However, only a few (<3/hpf) IgG4-positive plasma cells were seen to infiltrate the salivary glands of 50 patients with Sjögren’s syndrome, and serum IgG4 levels were not elevated in ten patients with Sjögren’s syndrome.8 Salivary gland function examined by sialochemistry and salivary gland scintigraphy was markedly impaired in many patients with AIP.40,97 Elevation of serum IgG4 levels and dense infiltration of IgG4-positive plasma cells in the salivary glands were usually detected in patients with sclerosing sialadenitis; furthermore, two of five patients with sclerosing sialadenitis developed AIP during follow-up.8,98 These findings suggest a close relationship between AIP and sclerosing sialadenitis. Furthermore, the salivary gland lesion associated with AIP is different from that of Sjögren’s syndrome.

Two reports dealing with IgG4-related sialadenitis have been published.10,11 Kitagawa et al.10 reported that dense infiltration of IgG4-positive plasma cells was detected in the salivary glands of 12 patients with sclerosing sialadenitis (Kuttner’s tumor), and five of these patients (five men; average age, 64.8 years) had associated sclerosing lesions in extrasalivary glandular tissue, such as is the case in AIP, while the remaining seven patients (three men and four women; average age, 64.4 years) had only salivary gland involvement. Yamamoto et al.11 reported that in seven patients (two men and five women; average age, 66.7 years) with Mikulicz’s disease, there was a marked elevation of serum IgG4 levels and dense infiltration of IgG4-positive plasma cells in the lachrymal and salivary glands, and that these findings were not were detected in patients with Sjögren’s syndrome. We experienced a patient with AIP showing enlargement of bilateral lacrimal glands that improved after steroid therapy.98 Thus, many cases of sclerosing sialadenitis, including Kuttner’s tumor and Mikulicz’s disease, could be salivary gland lesions of IgG4-related systemic disease.

Retroperitoneal fibrosis

In 1948, Ormond99 described two patients who presented with anuria caused by bilateral ureteral obstruction due to envelopment and compression of the ureters by an inflammatory retroperitoneal process identified as idiopathic retroperitoneal fibrosis. Idiopathic retroperitoneal fibrosis is an uncommon entity of obscure origin usually confined to the retroperitoneal space and the pelvic brim.

A total of ten patients (ten men; average age, 63.5 years), including our four patients, have been reported to have retroperitoneal fibrosis associated with AIP.46,100, 101, 102, 103 In three cases, retroperitoneal fibrosis occurred 10 to 18 months before the onset of AIP. Dense infiltration of IgG4-positive plasma cells and obliterative phlebitis were found in both the pancreas and retroperitoneal fibrous mass (Fig. 3e). These retroperitoneal fibrotic lesions associated with AIP seem to be retroperitoneal lesions of IgG4-related systemic disease. In all nine of the patients who were treated with steroids, both the retroperitoneal fibrosis and AIP were resolved. Recently, a case of a 52-year-old man with retroperitoneal and mediastinal fibrosis who exhibited elevation of serum IgG4 levels in the absence of AIP was reported.14

Lymphadenopathy

Little attention has been given to lymph node swelling in AIP patients. In a study using gallium-67 scintigraphy, pulmonary hilar gallium-67 uptake was found in 16 of 24 patients with AIP.104 In our series, abdominal lymphadenopathy of up to 2 cm in diameter was observed in five of eight patients at laparotomy, and cervical or mediastinal lymphadenopathy of up to 1.5 cm in diameter was observed in 7 of 28 patients on CT.8 In all these cases, the lymphadenopathy disappeared after steroid therapy. Furthermore, cervical lymphadenopathy was obvious in five of six patients with IgG4-related sclerosing sialadenitis. Dense infiltration of IgG4-positive plasma cells was detected in all abdominal lymph nodes (AIP, n = 6; and sclerosing sialadenitis, n = 1) and cervical lymph nodes (AIP, n = 2; and sclerosing sialadenitis, n = 3) (Fig. 3c). However, only a few IgG4-positive plasma cells were seen to infiltrate abdominal lymph nodes of patients with chronic alcoholic pancreatitis or pancreatic cancer, or cervical lymph nodes of patients with Sjögren’s syndrome.8

Sclerosing cholecystitis

In our series, thickening of the gallbladder was detected on US or CT in 11 of 32 (34%) patients with AIP. Dense infiltration of IgG4-positive plasma cells and lymphocytes, as well as transmural fibrosis, was detected in the gallbladder wall of six of eight examined patients.105

Interstitial pneumonia

A 63-year-old man had concurrent interstitial pneumonia and AIP, both of which improved after steroid therapy. Transbronchial lung biopsy showed dense infiltration of IgG4-positive plasma cells in the alveolar septum.106 Recently, Hirano et al.107 reported that 4 (four men; average age, 69.5 years) of 30 patients with AIP had pulmonary involvement, and they showed good response to steroid therapy.

Tubulointerstitial nephritis

Two cases (in a 64-year-old man108 and a 66-year-old man109) of tubulointerstitial nephritis associated with AIP have been reported. Both diseases improved after steroid therapy. The renal biopsy done in one case showed IgG4-positive staining along the tubular basement membrane and infiltration of IgG4-positive plasma cells into the tubulointerstitium.

Hepatic inflammatory pseudotumor

Hepatic inflammatory pseudotumor is a rare benign lesion characterized by polyclonal lymphoplasmacytic infiltration with fibrosis and is sometimes misdiagnosed as primary hepatic malignant tumor. In two reported cases (a 48-year-old man65 and a 79-year-old man110) of hepatic inflammatory pseudotumor associated with AIP, the tumor showed dense infiltration of IgG4-positive plasma cells, fibrosis, and obliterative phlebitis. Both the hepatic inflammatory pseudotumor and AIP improved after steroid therapy. Zen et al.12 found extensive and dense fibrosis with dense infiltration of IgG4-positive plasma cells and lymphocytes, and obliterative phlebitis was seen in the bile duct lesions of five patients (five men; average age, 65.0 years) with a hepatic inflammatory pseudotumor associated with sclerosing cholangitis. This suggests that these conditions could be included in a common disease entity.

Inflammatory pseudotumor of the lung

We treated a 63-year-old man who had a concurrent inflammatory pseudotumor of the lung and AIP, both of which improved after steroid therapy. The resected lung tumor showed dense infiltration of IgG4-positive plasma cells and lymphocytes intermixed with fibrosis and obliterative phlebitis. Zen et al.13 reported nine cases (five men, four women; average age, 56.8 years) with an inflammatory pseudotumor of the lung that had the same pathological findings as those mentioned above; no cases were associated with AIP, and two cases were associated with sclerosing sialadenitis or lymphadenopathy.

Other reported lesions associated with AIP are pseudotumor of the hypophysis,111 immune thrombocytopenic purpura,112,113 autoimmune sensorineural hearing loss,113 hypothyroidism,114 anosmia,115 and loss of taste.115

IgG4-related sclerosing disease

By histologically and immunohistochemically examining various organs of AIP patients, dense infiltration of IgG4-positive plasma cells as well as CD4- or CD8-positive T lymphocytes and fibrosis have been observed in the peripancreatic retroperitoneal tissue, bile duct wall, gallbladder wall, periportal area of the liver, salivary glands, as well as the pancreas of AIP patients.7,8,32 All extrapancreatic lesions associated with AIP such as sclerosing cholangitis, sclerosing sialadenitis, or retroperitoneal fibrosis show infiltration of abundant IgG4-positive plasma cells, but the infiltration is not detected in those of PSC, Sjögren’s syndrome, sialolithiasis, chronic alcoholic pancreatitis, or pancreatic cancer. Both pancreatic and extrapancreatic lesions of AIP respond well to steroid therapy, being different from PSC.

We therefore propose the existence of a novel clinicopathological entity, an IgG4-related sclerosing disease incorporating sclerosing pancreatitis, cholangitis, sialadenitis, and retroperitoneal fibrosis with lymphadenopathy. It is histopathologically characterized by extensive IgG4-positive plasma cell and T-lymphocyte infiltration of various organs. Major clinical manifestations are apparent in the pancreas, bile duct, salivary glands, and retroperitoneum, in which tissues fibrosis with obliterative phlebitis is pathologically induced. AIP is not simply a pancreatitis, but it is, in fact, a pancreatic lesion reflecting an IgG4-related systemic disease. Sclerosing cholangitis, sclerosing sialadenitis, and retroperitoneal fibrosis associated with AIP are different from PSC, Sjögren’s syndrome, and so-called idiopathic retroperitoneal fibrosis. Most IgG4-related sclerosing diseases have been found to be associated with AIP, but IgG4-related sclerosing diseases without pancreatic involvement have been reported. Some pseudotumors may be involved in this disease. In some cases, only one or two organs are clinically involved, while in others three or four organs are affected (Fig. 4). The disease occurs predominantly in elderly males, is frequently associated with lymphadenopathy, and responds well to steroid therapy. Serum IgG4 levels and immunostaining with anti-IgG4 antibody are useful in making the diagnosis.8,116 The precise pathogenesis and pathophysiology of IgG4-related sclerosing disease remain unclear (Table 1).
Fig. 4

Schematic illustration showing the relationship between IgG4-related sclerosing disease, autoimmune pancreatitis, sclerosing cholangitis, sclerosing sialadenitis, retroperitoneal fibrosis, and pseudotumor

Table 1

Clinicopathological findings of IgG4-related sclerosing disease

Systemic disease characterized histopathologically by extensive IgG4-positive plasma cell infiltration of various organs together with T lymphocytes

Major clinical manifestations are apparent in the organs in which tissues fibrosis with obstructive phlebitis is pathologically induced

 

Pancreas

Autoimmune pancreatitis

 

Bile duct

Sclerosing cholangitis

 

Gallbladder

Sclerosing cholecystitis

 

Salivary gland

Sclerosing sialadenitis

 

Retroperitoneum

Retroperitoneal fibrosis

Some pseudotumors may be involved in this disease

Possibility of close relationship to multifocal fibrosclerosis

Occasional association with lymphadenopathy

Elderly male preponderance

Frequent elevation of serum IgG4 levels

Favorite response to steroid therapy

Differentiation from malignant tumor is important.

Precise pathogenesis and pathophysiology remain unclear

Since malignant tumors are frequently suspected on initial presentation, IgG4-related sclerosing disease should be considered in the differential diagnosis to avoid unnecessary surgery.

Conclusion

AIP has many clinical, serological, morphological, and histopathological characteristic features. AIP should be diagnosed based on combination of these findings. In an elderly man presenting with obstructive jaundice and a pancreatic mass, AIP should be considered as one of the differential diagnoses to avoid unnecessary surgery.

We proposed a new clinicopathological entity of IgG4-related sclerosing disease. It is characterized by extensive IgG4-positive plasma cell and T-lymphocyte infiltration of various organs, and major clinical manifestations are apparent in the pancreas, bile duct, retroperitoneum, and salivary glands, in which tissues fibrosis with obliterative phlebitis is pathologically induced. Much work needs to be done internationally to understand the full spectrum of this disease.

Notes

Acknowledgment

This study was supported by Research for Intractable Disease of the Pancreas, Ministry of Health, Labour and Welfare of Japan.

References

  1. 1.
    Sarles, H, Sarles, JC, Muratoren, R, Guien, C 1961Chronic inflammatory sclerosing of the pancreas—an autonomous pancreatic disease?Am J Dig Dis6688698PubMedGoogle Scholar
  2. 2.
    Toki, F, Kozu, T, Oi, I 1992An usual type of chronic pancreatitis showing diffuse irregular narrowing of the entire main pancreatic duct on ERCP. A report of four casesEndoscopy24640Google Scholar
  3. 3.
    Yoshida, K, Toki, F, Takeuchi, T, Watanabe, S, Shiratori, K, Hayashi, N 1995Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitisDig Dis Sci4015611568PubMedGoogle Scholar
  4. 4.
    Okazaki, K 2003Autoimmune pancreatitis is increasing in JapanGastroenterology12515571558PubMedGoogle Scholar
  5. 5.
    Kim, KO, Kim, MH, Lee, SS, Seo, DW, Lee, SK 2004Autoimmune pancreatitis: it may be a worldwide entityGastroenterology1261214PubMedGoogle Scholar
  6. 6.
    Sutton, R 2005Autoimmune pancreatitis—also a Western diseaseGut54581583PubMedGoogle Scholar
  7. 7.
    Kamisawa, T, Funata, N, Hayashi, Y, Eishi, Y, Koike, M, Tsuruta, K,  et al. 2003A new clinicopathological entity of IgG4-related autoimmune diseaseJ Gastroenterol38982984PubMedGoogle Scholar
  8. 8.
    Kamisawa, T, Nakajima, H, Egawa, N, Funata, N, Tsuruta, K, Okamoto, A 2006IgG4-related sclerosing disease incorporating sclerosing pancreatitis, cholangitis, sialadenitis and retroperitoneal fibrosis with lymphadenopathyPancreatology6132137PubMedGoogle Scholar
  9. 9.
    Hamano, H, Kawa, S, Uehara, T, Ochi, Y, Takayama, M, Komatsu, K,  et al. 2005Immunoglobulin G4-related lymphoplasmacytic sclerosing cholangitis that mimics infiltrating hilar cholangiocarcinoma: part of a spectrum of autoimmune pancreatitis?Gastrointest Endosc62152157PubMedGoogle Scholar
  10. 10.
    Kitagawa, S, Zen, Y, Harada, K, Sasaki, M, Sato, Y, Minato, H,  et al. 2005Abundant IgG4-positive plasma cell infiltration characterizes chronic sclerosing sialadenitis (Kuttner’s tumor)Am J Surg Pathol29783791PubMedGoogle Scholar
  11. 11.
    Yamamoto, M, Harada, S, Ohara, M, Suzuki, C, Naishiro, Y, Yamamoto, H,  et al. 2005Clinical and pathological differences between Mikulicz’s disease and Sjogren’s syndromeRheumatology44227234PubMedGoogle Scholar
  12. 12.
    Zen, Y, Harada, K, Sasaki, M, Sato, Y, Tsuneyama, K, Haratake, J,  et al. 2004IgG4-related sclerosing cholangitis with and without hepatic inflammatory pseudotumor, and sclerosing pancreatitis-associated sclerosing cholangitis. Do they belong to a spectrum of sclerosing pancreatitis?Am J Surg Pathol2811931203PubMedGoogle Scholar
  13. 13.
    Zen, Y, Kitagawa, S, Minato, H, Kurumaya, H, Katayanagi, K, Masuda, S,  et al. 2005IgG4-positive plasma cells in inflammatory pseudotumor (plasma cell granuloma) of the lungHum Pathol36710717PubMedGoogle Scholar
  14. 14.
    Zen, Y, Sawazaki, A, Miyayama, S, Notsumata, K, Tanaka, N, Nakanuma, Y 2006A case of retroperitoneal and mediastinal fibrosis exhibiting elevated levels of IgG4 in the absence of sclerosing pancreatitis (autoimmune pancreatitis)Hum Pathol37239243PubMedGoogle Scholar
  15. 15.
    Okazaki, K, Uchida, K, Chiba, T 2001Recent concept of autoimmune-related pancreatitisJ Gastroenterol36293302PubMedGoogle Scholar
  16. 16.
    Kim, KP, Kim, MH, Song, MH, Lee, SS, Seo, DW, Lee, SK 2004Autoimmune chronic pancreatitisAm J Gastroenterol9916051616PubMedGoogle Scholar
  17. 17.
    Lara, LP, Chari, ST 2005Autoimmune pancreatitisCurr Gastroenterol Rep7101106PubMedGoogle Scholar
  18. 18.
    Horiuchi, A, Kawa, S, Akamatsu, T, Aoki, Y, Mukawa, K, Furuya, N,  et al. 1998Characteristic pancreatic duct appearance in autoimmune chronic pancreatitis: a case report and review of the Japanese literatureAm J Gastroenterol93260263PubMedGoogle Scholar
  19. 19.
    Koga, Y, Yamaguchi, K, Sugitani, A, Chijiiwa, K, Tanaka, M 2002Autoimmune pancreatitis starting as a localized formJ Gastroenterol37133137PubMedGoogle Scholar
  20. 20.
    Kamisawa, T, Egawa, N, Nakajima, H 2003Autoimmune pancreatitis is a systemic autoimmune diseaseAm J Gastroenterol9828112812PubMedGoogle Scholar
  21. 21.
    Toosi, MN, Heathcote, J 2004Pancreatic pseudotumor with sclerosing pancreato-cholangitis: is this a systemic disease? AmJ Gastroenterol99377382Google Scholar
  22. 22.
    Kawaguchi, K, Koike, M, Tsuruta, K, Okamoto, A, Tabata, I, Fujita, N 1991Lymphoplasmacytic sclerosing pancreatitis with cholangitis: a variant of primary sclerosing cholangitis extensively involving pancreasHum Pathol22387395PubMedGoogle Scholar
  23. 23.
    Ectors, N, Maillet, B, Aerts, R, Geboes, K, Donner, A, Borchard, F,  et al. 1997Non-alcoholic duct destructive chronic pancreatitisGut41263268PubMedCrossRefGoogle Scholar
  24. 24.
    Yadav, D, Notohara, K, Smyrk, TC, Clain, JE, Pearson, RK, Famell, MB,  et al. 2003Idiopathic tumefactive chronic pancreatitis: clinical profile, histology, and natural history after resectionClin Gastroenterol Hepatol1129135PubMedGoogle Scholar
  25. 25.
    Nishimori, I, Tamaoki, A, Kawa, S, Tanaka, S, Takeuchi, K, Kamisawa, T,  et al. 2006Influence of steroid therapy on the course of diabetes mellitus in patients with autoimmune pancreatitis: findings from a nationwide survey in JapanPancreas32244248PubMedGoogle Scholar
  26. 26.
    Research Committee of Intractable Diseases of the Pancreas. Result of nationwide survey on chronic pancreatitis in 2002 (in Japanese). In: Otsuki M editor. Annual Report of the Research Committee of Intractable Diseases of the Pancreas. Kitakyushu; 2004. p. 109-2Google Scholar
  27. 27.
    Pearson, RK, Longnecker, DS, Chari, ST, Smyrk, TC, Okazaki, K, Frulloni, L,  et al. 2003Controversies in clinical pancreatology. Autoimmune pancreatitis: does it exist?Pancreas27113PubMedGoogle Scholar
  28. 28.
    Hardacre, JM, Iacobuzio-Donahue, CA, Sohn, TA, Abraham, SC, Yeo, CJ, Lillemoe, KD,  et al. 2003Results of pancreaticoduodenectomy for lymphoplasmacytic sclerosing pancreatitisAnn Surg237853859PubMedGoogle Scholar
  29. 29.
    Abraham, SC, Wilentz, RE, Yeo, CJ, Sohn, TA, Cameron, JL, Boitnott, JK,  et al. 2003Pancreaticoduodenectomy (Whipple resections) in patients without malignancy: are they all “chronic pancreatitis”Am J Surg Pathol27110120PubMedGoogle Scholar
  30. 30.
    Hamano, H, Kawa, S, Horiuchi, A, Unno, H, Furuya, N, Akamatsu, T,  et al. 2001High serum IgG4 concentrations in patients with sclerosing pancreatitisN Engl J Med344732738PubMedGoogle Scholar
  31. 31.
    Hirano, K, Komatsu, Y, Yamamoto, N, Nakai, Y, Sasahira, N, Toda, N,  et al. 2004Pancreatic mass lesions associated with raised concentration of IgG4Am J Gastroenterol9920382040PubMedGoogle Scholar
  32. 32.
    Kamisawa, T, Funata, N, Hayashi, Y, Tsuruta, K, Okamoto, A, Amemiya, K,  et al. 2003Close relationship between autoimmune pancreatitis and multifocal fibrosclerosisGut52683687PubMedGoogle Scholar
  33. 33.
    Kamisawa, T, Egawa, N, Nakajima, H, Tsuruta, K, Okamoto, A, Hayashi, Y,  et al. 2005Gastrointestinal findings in patients with autoimmune pancreatitisEndoscopy3711271130PubMedGoogle Scholar
  34. 34.
    Kamisawa, T, Nakajima, H, Egawa, N, Hayashi, Y, Funata, N 2004Autoimmune pancreatitis can be confirmed with gastroscopyDig Dis Sci49155156PubMedGoogle Scholar
  35. 35.
    Okazaki, K, Uchida, K, Ohana, M, Nakase, H, Uose, S, Inai, M,  et al. 2000Autoimmune-related pancreatitis is associated with autoantibodies and Th1/Th2-type cellular immune responseGastroenterology118573581PubMedGoogle Scholar
  36. 36.
    Kawa, S, Ota, M, Yoshizawa, K, Horiuchi, A, Hamano, H, Ochi, Y,  et al. 2002HLA DRB10405-DQB10401 haplotype is associated with autoimmune pancreatitis in the Japanese populationGastroenterology12212641269PubMedGoogle Scholar
  37. 37.
    Kamisawa, T, Yoshiike, M, Egawa, N, Nakajima, H, Tsuruta, K, Okamoto, A,  et al. 2004Chronic pancreatitis in the elderly in JapanPancreatology4223227PubMedGoogle Scholar
  38. 38.
    Takayama, M, Hamano, H, Ochi, Y, Saegusa, H, Komatsu, K, Muraki, T,  et al. 2004Recurrent attacks of autoimmune pancreatitis result in pancreatic stone formationAm J Gastroenterol99932937PubMedGoogle Scholar
  39. 39.
    Horiuchi, A, Kawa, S, Hamano, H, Hayama, M, Kiyosawa, K 2002ERCP features in 27 patients with autoimmune pancreatitisGastrointest Endosc55494499PubMedGoogle Scholar
  40. 40.
    Kamisawa, T, Egawa, N, Inokuma, S, Tsuruta, K, Okamoto, A, Kamata, N,  et al. 2003Pancreatic endocrine and exocrine function and salivary gland function in autoimmune pancreatitis before and after steroid therapyPancreas27235238PubMedGoogle Scholar
  41. 41.
    Tanaka, S, Kobayashi, T, Nakanishi, K, Okubo, M, Murase, T, Hashimoto, M,  et al. 2000Corticosteroid-responsive diabetes mellitus associated with autoimmune pancreatitisLancet356910911PubMedGoogle Scholar
  42. 42.
    Tanaka, S, Kobayashi, T, Nakanishi, K, Okubo, M, Murase, T, Hashimoto, M,  et al. 2001Evidence of primary β-cell destruction by T-cells and β-cell differentiation from pancreatic ductal cells in diabetes associated with active autoimmune chronic pancreatitisDiabetes Care2416611667PubMedGoogle Scholar
  43. 43.
    Kamisawa, T, Nakamura, T, Egawa, N, Nakajima, H, Tsuruta, K, Okamoto, A 2006Digestion and absorption of patients with autoimmune pancreatitisHepatogastroenterology53138140PubMedGoogle Scholar
  44. 44.
    Kamisawa, T, Egawa, N, Nakajima, H, Tsuruta, K, Okamoto, A 2005Extrapancreatic lesions in autoimmune pancreatitisJ Clin Gastroenterol39904907PubMedGoogle Scholar
  45. 45.
    Kawa, S, Hamano, H 2003Autoimmune pancreatitis and bile duct lesionsJ Gastroenterol3812011203PubMedGoogle Scholar
  46. 46.
    Uchida, K, Okazaki, K, Asada, M, Yazumi, S, Ohana, M, Chiba, T 2003Case of chronic pancreatitis involving an autoimmune mechanism that extended to retroperitoneal fibrosisPancreas269294PubMedGoogle Scholar
  47. 47.
    Kamisawa, T, Egawa, N, Nakajima, H, Tsuruta, K, Okamoto, A, Kamata, N 2003Clinical difficulties in the differentiation of autoimmune pancreatitis and pancreatic carcinomaAm J Gastroenterol9826942699PubMedGoogle Scholar
  48. 48.
    Egawa, N, Irie, T, Tu, Y, Kamisawa, T 2003A case of autoimmune pancreatitis with initially negative autoantibodies turning positive during the clinical courseDig Dis Sci4817051708PubMedGoogle Scholar
  49. 49.
    Kamisawa, T, Okamoto, A, Funata, N 2005Clinicopathological features of autoimmune pancreatitis in relation to elevation of serum IgG4Pancreas312831PubMedGoogle Scholar
  50. 50.
    Kamisawa T, Chen PY, Tu Y, Nakajima H, Egawa N, Tsuruta K, et al. Pancreatic cancer with a serum IgG4 concentration. World J Gastroenterol 2006 (in press)Google Scholar
  51. 51.
    Irie, H, Honda, H, Baba, S, Kuroiwa, T, Yoshimitsu, K, Tajima, T,  et al. 1998Autoimmune pancreatitis: CT and MR characteristicsAJR Am J Roentgenol17013231327PubMedGoogle Scholar
  52. 52.
    Furukawa, N, Muranaka, T, Yasumori, K, Matsubayashi, R, Hayashida, K, Arita, Y 1998Autoimmune pancreatitis: radiologic findings in three histologically proven casesJ Comput Assist Tomogr22880883PubMedGoogle Scholar
  53. 53.
    Sahani, DV, Kalva, SP, Farrell, J, Maker, MM, Saini, S, Mueller, PR,  et al. 2004Autoimmune pancreatitis: imaging featuresRadiology233345352PubMedGoogle Scholar
  54. 54.
    Kamisawa, T, Chen, PY, Tu, Y, Nakajima, H, Egawa, N, Tsuruta, K,  et al. 2006MRI and MRCP findings in autoimmune pancreatitisWorld J Gastroenterol1229192922PubMedGoogle Scholar
  55. 55.
    Servais, A, Pestieau, SR, Detry, O, Honore, P, Belaiche, J, Boniver, J,  et al. 2001Autoimmune pancreatitis mimicking cancer of the head of pancreas: report of two casesActa Gastroenterol Belg64227230PubMedGoogle Scholar
  56. 56.
    Tabata, M, Kitayama, J, Kanemoto, H, Fukasawa, T, Goto, H, Taniwaka, K 2003Autoimmune pancreatitis presenting as a mass in the head of the pancreas: a diagnosis to differentiate from cancerAm Surg69363366PubMedGoogle Scholar
  57. 57.
    Kamisawa, T, Okamoto, A, Funata, N 2004Autoimmune pancreatitisGastrointest Endosc59865866PubMedGoogle Scholar
  58. 58.
    Kamisawa, T, Egawa, N, Shimizu, M, Igari, T 2005Autoimmune dorsal pancreatitisPancreas309495PubMedGoogle Scholar
  59. 59.
    Kamisawa, T, Tu, Y, Egawa, N, Nakajima, H, Tsuruta, K, Okamoto, A 2006Involvement of pancreatic and bile ducts in autoimmune pancreatitisWorld J Gastroenterol12612614PubMedGoogle Scholar
  60. 60.
    Hyodo, N, Hyodo, T 2003Ultrasonographic evaluation in patients with autoimmune-related pancreatitisJ Gastroenterol3811551161PubMedGoogle Scholar
  61. 61.
    Hirano, K, Shiratori, Y, Komatsu, Y, Yamamoto, N, Sasahira, N, Toda, N,  et al. 2003Involvement of the biliary system in autoimmune pancreatitis: a follow-up studyClin Gastroenterol Hepatol1453464PubMedGoogle Scholar
  62. 62.
    Kamisawa, T 2005Angiographic findings in patients with autoimmune pancreatitisRadiology236371PubMedGoogle Scholar
  63. 63.
    Nakamoto, Y, Saga, T, Ishimori, T, Higashi, T, Mamede, M, Okazaki, K,  et al. 2000FDG-PET of autoimmune-related pancreatitis: preliminary resultsEur J Nucl Med2718351838PubMedGoogle Scholar
  64. 64.
    Higashi, T, Saga, T, Nakamoto, Y, Ishimori, T, Fujimoto, K, Doi, R,  et al. 2003Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET)—usefulness and limitations in “clinical reality”Ann Nucl Med17261279PubMedGoogle Scholar
  65. 65.
    Kanno, A, Satoh, K, Kimura, K, Masamune, A, Asakura, T, Unno, M,  et al. 2005Autoimmune pancreatitis with hepatic inflammatory pseudotumorPancreas31420423PubMedGoogle Scholar
  66. 66.
    Notohara, K, Burgart, LJ, Yadav, D, Chari, S, Smyrk, TC 2003Idiopathic chronic pancreatitis with periductal lymphoplasmacytic infiltration. Clinicopathologic features of 35 casesAm J Surg Pathol2711191127PubMedGoogle Scholar
  67. 67.
    Zamboni, G, Luttges, J, Capelli, P, Frulloni, L, Cavallini, G, Pederzoli, P,  et al. 2004Histopathological features of diagnostic and clinical relevance in autoimmune pancreatitis: a study on 53 resection specimens and 9 biopsy specimensVirchows Arch445552563PubMedGoogle Scholar
  68. 68.
    Suda, K, Takase, M, Fukumura, Y, Ogura, K, Ueda, A, Matsuda, T,  et al. 2005Histopathologic characteristics of autoimmune pancreatitis based on comparison with chronic pancreatitisPancreas30355358PubMedGoogle Scholar
  69. 69.
    Song, MH, Kim, MH, Jang, SJ, Lee, SK, Lee, SS, Han, J,  et al. 2005Comparison of histology and extracellular matrix between autoimmune pancreatitis and alcoholic chronic pancreatitisPancreas30272278PubMedGoogle Scholar
  70. 70.
    Saito, T, Tanaka, S, Yoshida, H, Imamura, T, Ukegawa, J, Deki, T,  et al. 2002A case of autoimmune pancreatitis responding to steroid therapyPancreatology2550556PubMedGoogle Scholar
  71. 71.
    Chari, ST, Echelmeyer, S 2005Can histopathology be the “Gold Standard”“for diagnosing autoimmune pancreatitis?Gastroenterology12921182120PubMedGoogle Scholar
  72. 72.
    72 Members of the Criteria Committee for Autoimmune Pancreatitis of the Japan Pancreas Society2002Diagnostic criteria for autoimmune pancreatitis by the Japan Pancreas Society (in Japanese)Suizou (J Jpn Pancreas Soc)17585587Google Scholar
  73. 73.
    Okazaki, K, Kawa, S, Kamisawa, T, Naruse, S, Tanaka, S, Nishimori, I,  et al. 2006Clinical diagnostic criteria of autoimmune pancreatitis: revised proposalJ Gastroenterol41626631PubMedGoogle Scholar
  74. 74.
    Kim, KP, Kim, MH, Kim, JC, Lee, SS, Seo, DW, Lee, SK 2006Diagnostic criteria for autoimmune chronic pancreatitis revisedWorld J Gastroenterol1224872496PubMedGoogle Scholar
  75. 75.
    Levy, MJ, Wiersema, MJ, Chari, ST 2006Chronic pancreatitis: focal pancreatitis or cancer? Is there arole for FNA/biopsy? Autoimmune pancreatitisEndoscopy38e305Google Scholar
  76. 76.
    Kamisawa, T, Yu, Y, Nakajima, H, Egawa, N, Tsuruta, K, Okamoto, A 2006Usefulness of biopsying the major duodenal papilla to diagnose autoimmune pancreatitis: a prospective study using IgG4-immunostainingWorld J Gastroenterol1220312033PubMedGoogle Scholar
  77. 77.
    Ozden, I, Dizdaroglu, F, Poyanli, A, Emre, A 2005Spontaneous regression of a pancreatic head mass and biliary obstruction due to autoimmune pancreatitisPancreatology5300303PubMedGoogle Scholar
  78. 78.
    Wakabayashi, T, Motoo, Y, Kojima, Y, Makino, H, Sawabu, N 1998Chronic pancreatitis with diffuse irregular narrowing of the main pancreatic ductDig Dis Sci4324152425PubMedGoogle Scholar
  79. 79.
    Kamisawa, T, Egawa, N, Nakajima, H, Tsuruta, K, Okamoto, A 2004Morphological changes after steroid therapy in autoimmune pancreatitisScand J Gastroenterol3911541158PubMedGoogle Scholar
  80. 80.
    Taniguchi, T, Tanio, H, Seko, S, Nishida, O, Inoue, F, Okamoto, M,  et al. 2003Autoimmune pancreatitis detected as a mass in the head of the pancreas without hypergammaglobulinemia, which relapsed after surgery. Case report and review of the literatureDig Dis Sci4814651471PubMedGoogle Scholar
  81. 81.
    Padilla, D, Cubo, T, VilLarejo, P, Pardo, R, Jara, A, Plaza, R,  et al. 2005Response to steroid therapy of sclerosing cholangitis after duodenopancreatectomy due to autoimmune pancreatitisGut5413481349PubMedGoogle Scholar
  82. 82.
    Kamisawa, T, Yoshiike, M, Egawa, N, Nakajima, H, Tsuruta, K, Okamoto, A 2005Treating patients with autoimmune pancreatitis: results from a long-term follow-up studyPancreatology5234240PubMedGoogle Scholar
  83. 83.
    Kamisawa T, Wakabayashi T, Sawabu, N. Autoimmune pancreatitis in young adults. J Clin Gastroenterol 2006 (in press)Google Scholar
  84. 84.
    Kamisawa, T 2005Clinical subtype of autoimmune pancreatitisIntern Med44785786PubMedGoogle Scholar
  85. 85.
    Comings, DE, Skubi, KB, Eyes, JV, Motulsky, AG 1967Familial multifocal fibrosclerosisAnn Intern Med66884892PubMedGoogle Scholar
  86. 86.
    Clark, A, Zeman, RK, Choyke, PL, White, FM, Burrell, MI, Grant, EG,  et al. 1988Pancreatic pseudotumors associated with multifocal idiopathic fibrosclerosisGastrointest Radiol133032PubMedGoogle Scholar
  87. 87.
    Waldram, R, Kopelman, H, Tsantoulas, D, Williams, R 1975Chronic pancreatitis, sclerosing cholangitis, and sicca complex in two siblingsLancet1550552PubMedGoogle Scholar
  88. 88.
    Sjogren, I, Wengle, B, Korsgren, M 1979Primary sclerosing cholangitis associated with fibrosis of the submandibular glands and the pancreasActa Med Scand205139141PubMedCrossRefGoogle Scholar
  89. 89.
    Levey, JM, Mathai, J 1998Diffuse pancreatic fibrosis: an uncommon feature of multifocal idiopathic fibrosclerosisAm J Gastroenterol93640642PubMedGoogle Scholar
  90. 90.
    LaRusso, NF, Wiesner, RH, Ludwig, J, MacCarty, RL 1984Current concepts. Primary sclerosing cholangitisN Eng J Med310899903CrossRefGoogle Scholar
  91. 91.
    Wiesner, RH, Grambsch, PM, Dickson, ER, Ludwig, J, MacCarty, RC, Hunter, EB,  et al. 1989Primary sclerosing cholangitis: natural history, prognostic factor and survival analysisHepatology10430436PubMedGoogle Scholar
  92. 92.
    Nakazawa, T, Ohara, H, Sano, H, Ando, T, Aoki, S, Kobayashi, S,  et al. 2005Clinical differences between primary sclerosing cholangitis and sclerosing cholangitis with autoimmune pancreatitisPancreas302025PubMedGoogle Scholar
  93. 93.
    Kamisawa, T, Egawa, N, Tsuruta, K, Okamoto, A, Funata, N 2005Primary sclerosing cholangitis may be overestimated in JapanJ Gastroenterol40318319PubMedGoogle Scholar
  94. 94.
    Kuttner, H 1886Ueber entzundliche Tumoren der submaxillar SpeicheldruseBruns Beitr Klin Chir8815828Google Scholar
  95. 95.
    Schaffer, AJ, Jacobsen, AW 1927Mikulicz’s syndrome: a report of ten casesAm J Dis Child34327346Google Scholar
  96. 96.
    Muntefusco, PP, Geiss, AC, Bronzo, RL, Randall, S, Kahn, F, McKinley, MJ 1984Sclerosing cholangitis, chronic pancreatitis, and Sjogren’s syndrome: a syndrome complexAm J Surg147822826Google Scholar
  97. 97.
    Kamisawa, T, Tu, Y, Egawa, N, Sakaki, N, Inokuma, S, Kamata, N 2003Salivary gland involvement in chronic pancreatitis of various etiologiesAm J Gastroenterol98323326PubMedGoogle Scholar
  98. 98.
    Kamisawa, T, Nakajima, H, Hishima, T 2006Close relationship between chronic sclerosing sialadenitis and IgG4Intern Med J36527529PubMedGoogle Scholar
  99. 99.
    Ormond, JK 1948Bilateral ureteral obstruction due to envelopment and compression by an inflammatory retroperitoneal processJ Urol59950954Google Scholar
  100. 100.
    Hamano, H, Kawa, S, Ochi, Y, Unno, H, Shiba, N, Wajiki, M,  et al. 2002Hydronephrosis associated with retroperitoneal fibrosis and sclerosing pancreatitisLancet35914031404PubMedGoogle Scholar
  101. 101.
    Fukukura, Y, Fujiyoshi, F, Nakamura, F, Hamada, H, Nakajo, M 2003Autoimmune pancreatitis associated with idiopathic retroperitoneal fibrosisAJR181993995PubMedGoogle Scholar
  102. 102.
    Kamisawa, T, Matsukawa, M, Ohkawa, M 2005Autoimmune pancreatitis associated with retroperitoneal fibrosisJOP10260263Google Scholar
  103. 103.
    Kamisawa, T, Chen, PY, Tu, Y, Nakajima, H, Egawa, N 2006Autoimmune pancreatitis metachronously associated with retroperitoneal fibrosis with IgG4-positive plasma cell infiltrationWorld J Gastroenterol1229552957PubMedGoogle Scholar
  104. 104.
    Saegusa, H, Momose, M, Kawa, S, Hamano, H, Ochi, Y, Takayama, M,  et al. 2003Hilar and pancreatic gallium-67 accumulation is characteristic feature of autoimmune pancreatitisPancreas272025PubMedGoogle Scholar
  105. 105.
    Kamisawa, T, Tu, Y, Nakajima, H, Egawa, N, Tsuruta, K, Okamoto, A,  et al. 2006Sclerosing cholecystitis associated with autoimmune pancreatitisWorld J Gastroenterol1237363739PubMedGoogle Scholar
  106. 106.
    Taniguchi, T, Ko, M, Seko, S, Nishida, O, Inoue, F, Kobayashi, H,  et al. 2004Interstitial pneumonia associated with autoimmune pancreatitisGut53770PubMedGoogle Scholar
  107. 107.
    Hirano, K, Kawabe, T, Komatsu, Y, Matsubara, S, Togawa, O, Arizumi, T,  et al. 2006High-rate pulmonary involvement in autoimmune pancreatitisIntern Med J365861PubMedGoogle Scholar
  108. 108.
    Uchiyama-Tanaka, Y, Mori, Y, Kimura, T, Sonomura, K, Umemura, S, Kishimoto, N,  et al. 2004Acute tubulointerstitial nephritis associated with autoimmune-related pancreatitisAm J Kid Dis43e18e25PubMedGoogle Scholar
  109. 109.
    Takeda, S, Haratake, J, Kasai, T, Takeda, C, Takazakura, E 2004IgG4-associated idiopathic tubulointerstitial nephritis complicating autoimmune pancreatitisNephrol Dial Transplant19474476PubMedGoogle Scholar
  110. 110.
    Sasahira, N, Kawabe, T, Nakamura, A, Shimura, K, Shimura, H, Itobayashi, E,  et al. 2005Inflammatory pseudotumor of the liver and peripheral eosinophilia in autoimmune pancreatitisWorld J Gastroenterol11922925PubMedGoogle Scholar
  111. 111.
    Vliet, HJ, Perenboom, RM 2004Multiple pseudotumors in IgG4-associated multifocal systemic fibrosisAnn Intern Med141896897PubMedGoogle Scholar
  112. 112.
    Nakamura, A, Funatomi, H, Katagiri, A, Katayose, K, Kitamura, K, Seki, T,  et al. 2003A case of autoimmune pancreatitis complicated with immune thrombocytopenia during maintenance therapy with prednisoloneDig Dis Sci4819681971PubMedGoogle Scholar
  113. 113.
    Ohara, H, Nakazawa, T, Sano, H, Ando, T, Okamoto, T, Takada, H,  et al. 2005Systemic extrapancreatic lesions associated with autoimmune pancreatitisPancreas31232237PubMedGoogle Scholar
  114. 114.
    Komatsu, K, Hamano, H, Ochi, Y, Takayama, M, Muraki, T, Yoshizawa, K,  et al. 2005High prevalence of hypothyroidism in patients with autoimmune pancreatitisDig Dis Sci5010521057PubMedGoogle Scholar
  115. 115.
    Dooreck, BS, Katz, P, Barkin, JS 2004Autoimmune pancreatitis in the spectrum of autoimmune exocrinopathy associated with sialoadenitis and anosmiaPancreas28105107PubMedGoogle Scholar
  116. 116.
    Kamisawa, T 2006IgG4-related sclerosing diseaseIntern Med45125126PubMedGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 2006

Authors and Affiliations

  • Terumi Kamisawa
    • 1
  • Atsutake Okamoto
    • 2
  1. 1.Department of Internal MedicineTokyo Metropolitan Komagome HospitalTokyoJapan
  2. 2.Department of SurgeryTokyo Metropolitan Komagome HospitalTokyoJapan

Personalised recommendations